Luisella Toschi

TL;DR: BA 1436032 has been shown to significantly prolong survival of mice intracerebrally transplanted with human astrocytoma carrying the IDH1R132H mutation and is developed a pan-inhibitor targeting tumors with different IDH 1R132 mutations.

TL;DR: Together, BAY1436032 is highly effective against all major types of IDH1 mutant AML, including leukemic blast clearance, myeloid differentiation, depletion of leukmic stem cells and prolonged survival in two independent patient-derived xenograft IDH 1 mutant AMl mouse models.

TL;DR: The novel oral pan-mutant IDH1 inhibitor BAY-1436032 is active against all IDH 1R132 mutation types and shows strong anti-leukemic activity in two independent AML PDX mouse models and clinical development is ongoing with a first in man study with Bays-14 36032 inIDH1 mutant solid tumors.

TL;DR: The changes in amino acid metabolism induced in MCF10A, a human mammary epithelial cell line, by the sequential knock-in of K-Ras and PI3K mutant oncogenes may indicate the dependency of AA metabolism on the oncogene mutation pattern in human cancer.

TL;DR: In this paper, a 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives were used as selective blockers of TASK-1 and TASk-3 channels, for the treatment and prevention of breathing disorders including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring.